When you see Caladrius raise his arm for the Slash attack, dodge through to get behind him and get in a few hits. Dodging the Fire Orb attack can be a bit tricky, as you'll need to time your Dash ...

About Caladrius Biosciences Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease.

About Caladrius Biosciences Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease.

So, the natural question for Caladrius Biosciences (NASDAQ:CLBS) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative ...

To access replay, please dial (855) 859-2056 (Domestic) or (404) 537-3406 (International). At the system prompt, please enter the code 4166037 followed by the sign #. About Caladrius Biosciences ...

David Mazzo, Ph.D., current president and CEO of Caladrius, will become CEO of Lisata. He will be joined by David Slack, current president and CEO of Cend, as the new company’s president and ...

Caladrius to make an immediate investment of $10 million in Cend in connection with a development collaboration agreement to maintain development momentum of the Cend pipeline ...

Caladrius Biosciences Inc., a clinical-stage biopharmaceutical company based in Basking Ridge, has entered into a definitive merger agreement with San Diego-based Cend Therapeutics Inc.

--Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, provides a corporate update and reports ...

Caladrius Biosciences, Inc. (CLBS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in ...